Aclaris Therapeutis (ACRS) Strong Ph3 Results for A-101 a Significant De-Risking Event; PT to $32 - Jefferies

November 16, 2016 6:36 AM EST
Get Alerts ACRS Hot Sheet
Price: $29.28 +1.07%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade ACRS Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Jefferies analyst David Steinberg reiterated a Buy rating and boosted his price target on Aclaris Therapeutis (NASDAQ: ACRS) to $32.00 (from $29.00) after the company announced positive topline Ph3 data for A-101 in the treatment of seborrheic keratosis (SK), a common aesthetic dermatologic condition affecting 83M sufferers in the US.

Steinberg commented, "This is a significant de-risking event for ACRS and should position the co for US and EU regulatory filings in 1Q17/mid-17, respectively. We continue to see A-101 SK as a potential $500M+ peak sales opportunity and think that ACRS fits our M&A thesis."

For an analyst ratings summary and ratings history on Aclaris Therapeutis click here. For more ratings news on Aclaris Therapeutis click here.

Shares of Aclaris Therapeutis closed at $23.43 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

Jefferies & Co

Add Your Comment